Biovail - Pharma - Canslimwert - 500 Beiträge pro Seite

[wwwillion]

Nähere Infos im thread

Canslim - Kulanamit - O`Neil USA-Werte (Nasdaq-Board)

Thread: Canslim - Kulanamit - O´Neil - USA-Werte

wwwillion

[wwwillion]

6monats-chart



2-Jahreschart



wwwillion

[wwwillion]

Biovail hopes to keep the competition`s blood pressure on the rise. The company applies its timed-release drug-delivery systems to existing drugs that treat hypertension, obesity, and arthritis. Its branded antihypertensive Tiazac accounts for most of sales, but it has high hopes for its generic version of hypertensive Cardizem CD, which is awaiting regulatory approval. Teva Pharmaceuticals has exclusive US marketing rights over Cardizem and 11 other generics in the pipeline. Biovail also conducts research for and licenses its products to third parties; it markets Centocor`s Retavase (clot-busting) drug in Canada. Chairman Eugene Melnyk owns one-fourth of the company, which bought Fuisz Technologies.

Hoovers

[wwwillion]

Biovail-Interessenten,

Der Ausbruch nach oben ist erfolgt. $ 74,56 Schlußkurs. Da klingelt wieder die Kasse

wwwillion

[wwwillion]

Und hier die Erklärung:

Tuesday September 12, 8:59 am Eastern Time
Press Release
Procyon BioPharma has Received Patent Approval in Canada for Fibrostat(TM)
MONTREAL, QUEBEC--Procyon BioPharma announced today that the Canadian Intellectual Property Office has approved the patent application, No. 2,132,416, for FIBROSTAT(TM), a topical cream for the treatment of scars resulting from surgery or burns. Patents have already been issued in the United States, Australia and Japan, and approval of its patent application is pending in Europe.

FIBROSTAT(TM) addresses the largely unmet medical need of providing relief to patients suffering from the effects of scarring, pain and irritation following general surgery, plastic surgery and burns. FIBROSTAT(TM) was invented in Canada at the University of Manitoba by plastic surgeon, Dr. Ken Dolynchuk, and is exclusively licensed to Procyon BioPharma. In February 2000, Procyon BioPharma and Biovail Corporation [NYSE:BVF - news] announced a licensing agreement for the Canadian marketing of FIBROSTAT(TM). The annual Canadian market potential for FIBROSTAT(TM) is estimated at $25 million and the world market potential is expected to exceed $500 million.

Procyon BioPharma Inc. is a publicly listed, biopharmaceutical Company focused principally on advancing two powerful platform technologies that have the potential to diagnose and treat cancer. Procyon`s non-pathogenic Antinuclear Autoantibodies (ANAs) bind specifically to multiple cancer cell types strongly enhancing the immune response to cancer cells. Prostate Secretory Protein (PSP(94)) is a naturally occurring human protein that has the potential to treat prostate cancer by inhibiting abnormal prostate cell growth. In addition, the estimation of PSP(94) levels in prostate cancer patients may have prognostic and diagnostic applications. Procyon also has two late-stage products: FIBROSTAT(TM), a topical cream for the management of newly formed scars following surgery or burns and COLOPATH(TM), a rapid, non-invasive screening test for colorectal cancer.

Procyon`s shares trade on the Toronto Stock Exchange under the ticker symbol, PBP.

[wwwillion]

und der Boss hat noch mehr davon:

wwwillion

Eugene Melnyk, 41, Barbados and New York City
$1.55 billion

Pharmaceuticals

Rank last year: 43

Eugene Melnyk, chairman of high-flying pharmaceutical company Biovail Corp., is close to a billion dollars richer than he was a year ago. If you pulled in a cool bill in a year, how would you celebrate? Melnyk went on an equine spending spree, shelling out close to

$20 million for 62 thoroughbred racehorses—adding to a prestigious stable that includes Archer’s Bay, winner of the 1998 Queen’s Plate. For good measure, Melnyk also picked up a new Gulfstream jet. Biovail, which specializes in developing time-release capsules of brand-name drugs, had a banner year. It added antidepressant and migraine treatments to its existing drug lineup, which includes its first success, Tiazac, prescribed for hypertension and angina. Melnyk, a onetime pharmaceutical salesman who bought Biovail in 1989, now spends most of his time at his clifftop tax haven in Barbados.

[wwwillion]

Und hier noch ein Hinweis für alle Zuspätkommer:

obige Meldung ist in den USA noch gänzlich unbekannt, auch in den boards wurde bis jetzt gerätselt, warum Biovail plötzlich einen solchen Anstieg zu verzeichnen hatte.
Vielleicht läßt sich heute zum Start noch was mitnehmen

wwwillion

[epicuraul]

wwwillion, willkommen bei den biovailern,
zusammen mit andrx empfehle ich hier im board diese aktie schon seit monaten in allen möglichen threads. einige haben sich dann zugunsten von andrx entschieden, weil die einfach besser gelaufen ist.
biovail gehört seit 7/99 zu meinen lieblingsaktien im depot.
im märz 00 habe ich dann in 2 tranchen liqudiert- um dann im april (etwas zu früh) wieder einzusteigen.
ich bin von der firma ziemlich überzeugt und denke, dass sie weiter sehr gute gewinne bringen könnte.
allerdings ist die aktie nichts für zocker.

gruß
epicuraul

[wwwillion]

Hallo epicuraul,

habe seinerzeit nach biovail hier in w-o gesucht- leider ohne Ergebnis. Umso mehr freue ich mich, dass noch ein paar Exoten wissen, was gut ist.

Neueste Info:

Reuters, 09/14/2000 09:37
NYSE DELAY (NYSE:BVF_.T) ORDER IMBALANCE LAST 110
Copyright 2000, Reuters News Service

Sag mir doch mal, wie die anderen threads zu biovail heißen.

wwwillion

[wwwillion]

BusinessWire, 09/19/2000 07:47
Biovail Initiates Tramadol Phase III Clinical Trials

TORONTO--(BW HealthWire)--Sept. 19, 2000--Biovail Corporation (NYSE:BVF) (TSE:BVF) today announced that they have entered Phase III clinical trials for a once-daily version of Tramadol. Tramadol is currently marketed in the United States by a division of Johnson and Johnson and is only available in an immediate-release, three to four times per day dosage format. Sales for the existing immediate-release version of Tramadol for the twelve months ended July 2000 were in excess of $475 million. Tramadol is indicated for the treatment of a variety of chronic pain syndromes with associated moderate to moderately severe pain. Pain is a common symptom of many diseases and is generally seen in everyday clinical practice.

Biovail is initiating two double-blind efficacy studies for moderate to moderately severe pain. Patient dosing for these studies is 12 weeks in duration and the Company expects the studies to be completed in approximately one year. Biovail also stated that it is in late stage development of additional novel once-daily controlled-release formulations in the anxiety disorders therapeutic class. Biovail anticipates the initiation of additional Phase III clinical trials for once-daily formulations that are currently only available in multi-dose formats over the coming months.

Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration and manufacture of drug products utilizing advanced drug delivery technologies.

[mitie]

Numbers of Brokers Recommending (09/18/00)
Strong Buy 3
Moderate Buy 4
Hold 2
Moderate Sell 0
Strong Sell 0

Current Average Recommendation (1.0=Strong Buy, 5.0=Strong Sell): 1.9
Last Weeks Average Recommendation: 1.8
Change In Average Recommendation: -0.1

[wwwillion]

Bei schwachem Markt +7% zu neuem ATH - da kommt Freude auf

wwwillion

[wwwillion]

Heute regnet es positive Nachrichten

1. Biovail erhält endgültige Zulassung für Procardia XL

2. Biovail kündigt 2:1 Aktiensplit an

3. Nifedipine erhält ebenfalls Zulassung von der FDA.

Da kommt Freude auf. Neue ATHs getestet. Derzeit Kurs bei $ 85

wwwillion



BusinessWire, 09/28/2000 07:48
Biovail Receives Procardia XL Final Approval; Marketing Partner Teva Launching Immediately; Biovail Also Announces a 2-1 Stock Split

TORONTO--(BW HealthWire)--Sept. 28, 2000--Biovail Corporation (NYSE:BVF)(TSE:BVF) today announced it has received final approval in the U.S. from the Food and Drug Administration (FDA) for its generic version of Procardia XL. Teva Pharmaceuticals will begin launching this product immediately. Procardia XL is indicated for the treatment of hypertension and angina. Branded sales of Procardia XL in the United States for the twelve months ended June 30, 2000 were in excess of $461 million.

Additionally, Biovail announced today that the Board of Directors of the Corporation approved a stock split of the common shares on the basis of two common shares for each one common share held. Additional common shares resulting from the stock split will be issued to shareholders of record as of the close of business on October 10, 2000 and certificates representing such shares will be mailed to shareholders on or about October 16, 2000. The shares will begin trading on a split basis on October 5, 2000 on The Toronto Stock Exchange and on October 16, 2000 on the New York Stock Exchange under the same stock symbol of "BVF".

Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration and manufacture of drug products utilizing advanced drug delivery technologies. Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration and manufacture of drug products utilizing advanced drug delivery technologies.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission.

[wwwillion]

BusinessWire, 09/29/2000 11:06
Option Exercised to Purchase Intelligent Polymers Limited

HAMILTON, Bermuda--(BUSINESS WIRE)--Sept. 29, 2000--Intelligent Polymers Limited (AMEX:IXP) ("Intelligent Polymers") announced today that it has received notice from Biovail Laboratories Inc., a wholly-owned subsidiary of Biovail Corporation (NYSE:BVF)(TSE:BVF) ("Biovail"), relating to the transfer of the option to purchase all the issued and outstanding common shares of Intelligent Polymers to a company formed by a private investor group (the "Company") which has subsequently exercised the option to purchase all Intelligent Polymers common shares for $39.06 per share, payable in cash. Biovail has the right to acquire the Company from the private investor group at any time for the same amount of consideration plus a fee.

A Schedule 13E-3 Transaction Statement was filed with the Securities and Exchange Commission in connection with the transaction.

Instructions and letters of transmittal have been sent to the holders of Intelligent Polymers Common Shares by the paying agent, ChaseMellon Shareholder Services, L.L.C. Intelligent Polymers Common Shares will cease to trade on the AMEX on September 29, 2000.

Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration and manufacture of drug products utilizing advanced drug delivery technologies.

Intelligent Polymers was formed in 1997 primarily to develop once-daily controlled release versions of selected drugs marketed only in immediate release form or in controlled release form requiring multiple daily dosing whose patents have or will have expired upon the anticipated receipt of FDA marketing approval.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.

[wwwillion]

Bei schwachem Markt +6,7% zu neuem ATH - da kommt erneut Freude auf

wwwillion

[wwwillion]

Da wurden wir Kleinktionäre wieder mal über den Tisch gezogen. Das ist eine Riesenschweinerei.

Banc of America hat Biovail nach der Kursrally downgegraded. Begründung: Nicht die Unternehmenszahlen seien schlechter geworden, sondern durch die zunehmende Generics-Konkurrenz.

Banc of America downgrades not because of valuation but increased competition from generics

Dabei hat Merril Lynch von drei Tagen seine Kaufempfehlung wiederholt:

Merrill Lynch reiterated buy rating Sept 28. However, it did not give a target price this time. The main points of the report include:

1. BVF`s US marketing partner, Teva, launched generic 60 mg Procardia XL in the US immediately after the FDA approval. Pfizer`s sales of 60 mg Procardia XL in the US were US$230 million in 1999.

2. BVF is the first generic filer for the 60 mg dose and will receive a 180-day period of exclusivity. However, the impact of BVF`s exclusivity may be partly offset by Mylan`s sales of discounted versions of all doses of PFE`s product. MYL`s discounted version represents approximatedly 60% of new prescriptions. MYL is selling the drug at a 10-15% discount to PFE`s price.

3. The timming of the launch of BVF`s generic 30 mg Procardia XL remains unclear, since Mylan, the first generic filer on the 30 mg dose, has not launched its product.

4. BVF is likely to launch 60 mg Adalat CC in the very near term. The 30-mounth delay afforded to Bayer`s product expires in late September.

5. BVF anounced a 2 for 1 stock split. Shares are expected to trade post-split on Oct. 5 on the TSE and on Oct. 16 on the NYSE.

6. Upcoming milestones include: a)entry into Phase III trials of bupropion and metformin, b)disclosure of plans to deal with the pending genericization of Tiazac as early as Feb 2001, c)acquisition of a US sale force, d) filing of a new drug application for once daily buspirone.

So wird man verarscht.

wwwillion

[wwwillion]

Andrx Receives Approval for Generic Form of Biovail Drug
(12:12 EST)
Biovail Corp. [T.BVF] -$16.35 to $114.50 CDN$
Shares of Biovail have dropped 12% on news that Andrx Corp. [ADRX] has received tentative approval from the U.S. Food and Drug Administration to make a generic form of Biovail`s best-selling product, Tiazac. The drug, used to treat chronic stable angina, will be marketed as Taztia by Andrx.

[gigalooser]

finde ich echt nicht gut was da passiert. auch wenn andrx vermutlich davon profitiert
wenn sich die generika jetzt auch noch bekriegen, dann ist es meiner meinung nach vorbei damit das diese werte relativ wenig volatilität aufweisen. mir wäre es lieber die würden sie auf die pharmas konzentrieren und sich nicht gegenseitig die augen aushacken. endet ja nur darin das die marge schmäler wird.

schade

gl

[wwwillion]

Andrx fiel ebenso - um 2,8% - das verstehe wer will.

Überreaktion, das alles

wwwillion

[wwwillion]

Das war ein Blutrausch. Runter auf $ 67. Und bei geschlossenen Banken in Deutschland waren einem auch noch die Hände gebunden

wwwillion

[gony]

Kann mir einer veraten warum die so abgestürzt sind ? Wann kommt der Split?
Was haltet ihr von helix bio?

[wwwillion]

es steht doch am 3.10. in diesem thread. Anschließend haben sie sich aber relativ erholt, weil Biovail gleich ´ne gute Nachricht nachgeschoben hat.

wwwillion

[wwwillion]

Hier die Institutionellen von Biovail:

http://12.14.65.32/silicon?page=holders&compid=bvf

wwwillion

[wwwillion]

October 26, 2000 07:02

Biovail Reports Record Third Quarter Financial Results; Diluted EPS Increases 69% To $0.27-Excluding Charges
TORONTO, ONTARIO--Biovail Corporation (NYSE, TSE:BVF) today reported record financial results for the third quarter and nine months ended September 30, 2000. Total revenues in the third quarter increased by 99% and net income increased by 140% (excluding charges) and diluted earnings per share increased by 69% to $0.27 on a post split basis (or $0.54 on a pre-split basis). Year-to-date revenues increased 82% and net income and diluted earnings per share (excluding charges) have increased 116%and 53% respectively. The Company`s Common Shares split on a 2 for1 basis in September 2000 and therefore all reported financial results take into effect this stock split.
Eugene Melnyk, Chairman of the Board, commented, "We are pleased with the growth in our product sales revenues and the execution ofour revenue diversification strategies including the launch of several significant generic products. With the recent acquisition of DJ Pharma, Biovail has significantly enhanced the value of its late stage product development pipeline. This strong revenue and income growth in 2000 and our on-going strategic initiatives makesBiovail comfortable with a diluted EPS estimate of $0.78 on a postsplit basis for 2000 and EPS growth of at least 30% in 2001 and 2002, in both cases excluding certain significant items including the write-off of acquired research and development.

"The acquisition of DJ Pharma," Mr. Melnyk continued, "reduced Biovail`s interest in early out-licensing of any of its branded products under development in return for passing on a portion of the developmental and clinical costs associated with the products to a partner. Alternatively, Biovail believes it can maximize the value of its pipeline by accelerating its developmental efforts through funding available from Intelligent Polymers Limited."

"This record performance," added Mr. Howling, "was driven by a number of factors including the expansion of the number of products manufactured and sold by Biovail; 13 products in the third quarter 2000 versus only 8 products sold in the third quarter of 1999, and by an increase in research and development revenues. Product sales revenues have increased 90% for the 9 months ended September 30th, 2000 due to these products launches.

Certain items have been excluded in calculating the net income anddiluted earnings per share figures above. The financial results described above exclude the anticipated third quarter 2000 charge for acquired research and development of $141.5 million related tothe Intelligent Polymers Limited products and a third quarter 1999equity loss charge related to Fuisz Technologies Ltd. of $57.1 million, which includes a proportional charge for Fuisz related acquired in-process research and development.

Also, during the first quarter of 2000, the Company repurchased all of its outstanding 10 7/8% Senior Notes at a premium resultingin an extraordinary charge of $20.0 million. Including the chargesidentified above, the Company reported a net loss of $102.6 million or $0.79 for third quarter 2000 versus a net loss of $41.0million or $0.42 per share for the third quarter 1999 and a net loss of $87.2 million or $0.68 per share for the nine months endedSeptember 30th, 2000 versus a net loss of $22.7 million or $0.23 per share for the equivalent 1999 period.

As in the past, Biovail is pleased to broadcast its earnings conference call and encourages its stakeholders to listen to the call over our web site at www.biovail.com.

Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of drug products utilizing advanced drug delivery technologies.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA and TPP approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.



BIOVAIL CORPORATION
CONSOLIDATED BALANCE SHEETS
IN ACCORDANCE WITH U.S. GAAP
(All dollar amounts are expressed in thousands of U.S. dollars)
(Unaudited)

September 30, December 31,
2000 1999
------------ -------------
A S S E T S
CURRENT
Cash and cash equivalents $ 348,702 $ 178,086
Short-term investments 49,169 65,893
Accounts receivable 86,224 60,571
Inventories 23,533 12,701
Assets held for disposal - 20,000
Deposits and prepaid expenses 4,955 3,172
------------ -------------
512,583 340,423

LONG-TERM INVESTMENTS 2,071 12
PROPERTY, PLANT AND EQUIPMENT, net 48,834 45,300
OTHER ASSETS, net 92,418 86,478
------------ -------------
$ 655,906 $ 472,213
------------ -------------
------------ -------------

L I A B I L I T I E S
CURRENT
Accounts payable $ 20,278 $ 22,685
Accrued liabilities 27,090 31,107
Income taxes payable 8,364 3,585
Customer prepayments 10,467 4,962
Deferred tax liability 336 336
Current portion of long-term debt 512 12,016
------------ -------------
67,047 74,691

DEFERRED TAX LIABILITY 4,447 4,698
CONVERTIBLE SUBORDINATED PREFERRED
EQUIVALENT DEBENTURES 300,000 -
LONG-TERM DEBT - 125,488
------------ -------------
371,494 204,877
------------ -------------

S H A R E H O L D E R S ` E Q U I T Y
Common shares 478,055 373,962
Warrants 8,244 8,244
Warrant subscription receivable - (2,287)
Deficit (201,047) (113,843)
Accumulated other comprehensive
income (loss) (840) 1,260
------------ -------------
284,412 267,336
------------ -------------
$ 655,906 $ 472,213
------------ -------------
------------ -------------


BIOVAIL CORPORATION
CONSOLIDATED STATEMENTS OF LOSS
IN ACCORDANCE WITH U.S. GAAP
(All dollar amounts except per share data are expressed in thousands
of U.S. dollars)
(Unaudited)

Three Months Ended Nine Months Ended
September 30, September 30,
-------------------------- -------------------------
2000 1999 2000 1999
------------ ------------ ----------- ------------
REVENUE
Product sales $ 50,296 $ 28,730 $ 126,289 $ 66,271
Research and
development 33,284 11,254 59,280 25,209
Royalty and
licensing 5,113 4,637 10,426 16,139
------------ ------------ ----------- ------------
88,693 44,621 195,995 107,619
------------ ------------ ----------- ------------
EXPENSES
Cost of goods
sold 16,798 8,946 41,371 21,833
Research and
development 22,713 7,699 48,421 19,482
Selling,
general and
administrative 10,954 8,038 32,352 21,304
Acquired
research and
development 141,500 -- 141,500 --
------------ ------------ ----------- ------------
191,965 24,683 263,644 62,619
------------ ------------ ----------- ------------
OPERATING INCOME
(LOSS) (103,272) 19,938 (67,649) 45,000
EQUITY LOSS
(See below) -- (57,142) -- (57,142)
INTEREST INCOME
(EXPENSE), net 3,102 (2,722) 5,219 (8,171)
------------ ------------ ----------- ------------
LOSS BEFORE
INCOME TAXES (100,170) (39,926) (62,430) (20,313)
PROVISION FOR
INCOME TAXES 2,478 1,062 4,735 2,370
------------ ------------ ----------- ------------
LOSS BEFORE
EXTRAORDINARY
ITEM (102,648) (40,988) (67,165) (22,683)
EXTRAORDINARY
ITEM - Premium
paid on early
extinguishment
of U.S. Dollar
Senior Notes -- -- (20,039) --
------------ ------------ ----------- ------------
NET LOSS $ (102,648) $ (40,988) $ (87,204) $ (22,683)
------------ ------------ ----------- ------------
------------ ------------ ----------- ------------
BASIC LOSS
PER SHARE
Loss before
extraordinary
item $ (0.79) $ (0.42) $ (0.52) $ (0.23)
Extraordinary
item -- -- (0.16) --
------------ ------------ ----------- ------------
Net loss $ (0.79) $ (0.42) $ (0.68) $ (0.23)
------------ ------------ ----------- ------------
------------ ------------ ----------- ------------
DILUTED LOSS
PER SHARE
Loss before
extraordinary
item $ (0.79) $ (0.42) $ (0.52) $ (0.23)
Extraordinary
item -- -- (0.16) --
------------ ------------ ----------- ------------
Net loss $ (0.79) $ (0.42) $ (0.68) $ (0.23)
------------ ------------ ----------- ------------
------------ ------------ ----------- ------------

WEIGHTED AVERAGE
NUMBER OF
COMMON SHARES
OUTSTANDING
Basic 129,739,000 97,804,000 128,285,000 97,804,000
------------ ------------ ----------- ------------
------------ ------------ ----------- ------------
Diluted 146,377,000 101,668,000 143,402,000 101,668,000
------------ ------------ ----------- ------------
------------ ------------ ----------- ------------

Equity loss includes a charge for in-process research and development
of $57,120, related to the investment in Fuisz Technologies Ltd.

BIOVAIL CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
IN ACCORDANCE WITH U.S. GAAP
(All dollar amounts are expressed in thousands of U.S. dollars)
(Unaudited)

Nine Months Ended
September 30,
--------------------
2000 1999
--------- ---------

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss $ (87,204) $ (22,683)
Depreciation and amortization 14,926 4,960
Deferred income tax recovery (252) -
Acquired research and development 141,500 -
Extraordinary item - Premium paid
on early extinguishment
of U.S. Dollar Senior Notes 20,039 -
Equity loss - 57,142
Compensation cost for employee stock options - 1,350
--------- ---------
89,009 40,769
Change in non-cash operating items (42,802) 13,950
--------- ---------
46,207 54,719
--------- ---------
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property,
plant and equipment, net (11,074) (5,281)
Investment in IPL Acquireco 2000 Ltd. (141,500) -
Maturity of short-term investments, net 16,725 -
Acquisition of long-term investments, net (2,273) -
Proceeds from assets held for disposal 20,000 -
Decrease in other assets 333 -
Investment in Fuisz Technologies Ltd. - (77,479)
Acquisition of product rights - (2,203)
Repayment of executive stock
purchase plan loans - 719
--------- ---------

(117,789) (84,244)
--------- ---------
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common shares 104,093 2,985
Repurchase of common shares - (30,593)
Issuance of Convertible Subordinated
Preferred Equivalent Debentures,
net of financing costs 288,500 -
Repurchase of U.S. Dollar Senior Notes (141,017) -
Reduction in other long-term debt (11,432) (667)
Collection of warrant subscription receivable 2,287 2,383
--------- ---------
242,431 (25,892)
--------- ---------
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND
CASH EQUIVALENTS (233) 76
--------- ---------

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 170,616 (55,341)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 178,086 78,279
--------- ---------

CASH AND CASH EQUIVALENTS, END OF PERIOD $348,702 $ 22,938
--------- ---------
--------- ---------




FOR FURTHER INFORMATION PLEASE CONTACT:

Biovail Corporation
Ken Howling
[phone]

INDUSTRY: DRG
SUBJECT: ERN

[wwwillion]

BusinessWire, N/A

Biovail Added to S&P / Toronto Stock Exchange - TSE - 60 Index, Listing to Commence November 2, 2000

TORONTO--(BW HealthWire)--Nov. 1, 2000--Biovail Corporation (NYSE:BVF) (TSE:BVF) announced today that it has received notification that the Company will be added to the healthcare sector of the Standard & Poors / Toronto Stock Exchange 60 Index, effective Thursday, November 2, 2000.

Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of drug products utilizing advanced drug delivery technologies.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission.

[tellekomm]

@ wwwillion

was war gestern bei biovail los ?
Giebs dafuer fundmentale gründe oder sind sie durch´s
schlechte umfeld so abgesagt ?

tellekomm